Zentiva Pharma GmbH secures contract for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Rivaroxaban, ATC B01AF01 for the period 01042026 - 30062026

Germany, Sept. 2 -- Germany based Zentiva Pharma GmbH has secured contract from DAK-Gesundheit for Pharmaceutical products - Conclusion of a non-exclusive discount agreement in accordance with Section 130a Paragraph 8 SGB V for the active ingredient Rivaroxaban, ATC B01AF01 for the period 01042026 - 30062026. The value of the contract is not disclosed.

Published by HT Digital Content Services with permission from Pivotal Sources....